POAI Form 3 Filed by Interim CFO Joshua Blacher; No Beneficial Ownership

Rhea-AI Filing Summary

Joshua Blacher, identified as Interim CFO and an officer of Predictive Oncology Inc. (POAI), filed an initial Form 3 disclosing that he does not beneficially own any securities of the issuer. The report lists the relevant event date as 10/01/2023 and includes a signed remark that the Form 3 is being filed late due to an inadvertent administrative oversight; the filer states he is submitting the form promptly upon discovery and intends to comply with future Section 16(a) filing requirements. No non-derivative or derivative holdings are reported on this form.

Positive

• Initial disclosure made to satisfy Section 16(a) requirements despite being late
• Clear statement of no beneficial ownership, eliminating immediate insider-holding questions

Negative

• Late filing due to an administrative oversight, indicating a lapse in reporting controls

Insights

Securities Compliance Analyst

TL;DR: Officer filed an initial Form 3 reporting no holdings, but the filing was late and remedial disclosure was made.

The filing is procedural: an initial beneficial ownership statement was submitted by the Interim CFO showing zero direct or indirect holdings. From a compliance perspective, the late filing is noteworthy because Section 16(a) requires prompt reporting of such events; however, the filing includes a clear explanation attributing the delay to an administrative oversight and an assertion of intent to comply going forward. There is no reported ownership that would create immediate insider trading or disclosure obligations tied to securities transfers.

Corporate Governance Specialist

TL;DR: Governance impact is minimal: no holdings disclosed, but late filing raises internal control questions.

The substantive content shows no securities beneficially owned by the reporting officer, so there is no change to ownership structure. The admission of a late filing suggests a weakness in internal recordkeeping or reporting processes; the company and the reporting person should ensure controls are in place to prevent future lapses. Absent additional violations or repeated delays, this single remedial filing is unlikely to be material to investors.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Blacher Joshua

(Last) (First) (Middle)

C/O PREDICTIVE ONCOLOGY INC.

91 43RD STREET, SUITE 110

(Street)

PITTSBURGH PA 15201

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2023

3. Issuer Name and Ticker or Trading Symbol
Predictive Oncology Inc. [ POAI ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 3 is being filed late due to an inadvertent administrative oversight. Upon discovery of the oversight, the Reporting Person is filing this Form 3 promptly and intends to comply with all future filing requirements under Section 16(a) of the Securities Exchange Act of 1934.

No securities are beneficially owned.

	/s/ Josh Blacher	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 3 filed by Joshua Blacher for POAI disclose?

The Form 3 states that Joshua Blacher (Interim CFO/officer) does not beneficially own any securities of Predictive Oncology Inc.

When is the event date reported on the Form 3 for POAI?

The Form 3 lists the event date as 10/01/2023.

Was the Form 3 filed on time?

No. The filing states it was submitted late and attributes the delay to an inadvertent administrative oversight.

Does the filing report any derivative or non-derivative holdings?

No. The form explicitly states no securities are beneficially owned, and no derivative securities are listed.

What corrective action does the reporting person state?

The reporting person indicates he is filing the Form 3 promptly upon discovery and intends to comply with future Section 16(a) requirements.